Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Dr. Raman has succeeded Victoria Richon
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Subscribe To Our Newsletter & Stay Updated
